6509 5-FU/l-LV (RPMI) versus S-1 as first-line therapy in patients with advanced gastric cancer: a randomized phase III non-inferiority trial. (ISO-5FU10 Study Group trial)

Sawaki, Akira; Yamaguchi, K.; Nabeya, Yoshihiro; Sakai, Yasuyuki; Osanai, Hiroyuki; Denda, Tadamichi; Furue, H; Kurihara, M.

doi:10.1016/s1359-6349(09)71231-5

Cited by 17 publications

(19 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, 5FUci will be the current first choice for patients with bowel obstruction due to peritoneal metastases, but its effect on massive ascites remains elusive. On the other hand, another domestic phase III trial (ISO-5FU10) has shown non-inferiority of the 5FU + leucovorin (LV) combination against S-1 [52]. Thus, 5FU + LV, which can be delivered in the outpatient clinic, is another option for patients with relatively good general status.…”

Section: Appendix: Clinical Questionsmentioning

confidence: 99%

Japanese gastric cancer treatment guidelines 2014 (ver. 4)

2016

Gastric Cancer

2,052

693

View full text Add to dashboard Cite

Section: Appendix: Clinical Questionsmentioning

confidence: 99%

Japanese gastric cancer treatment guidelines 2014 (ver. 4)

2016

Gastric Cancer

2,052

693

View full text Add to dashboard Cite

“…1 ). In total, 15 studies containing 4,713 patients were eligible 8 – 12 , 14 , 17 – 25 . The number of patients that received capecitabine-based, 5-FU-based and S-1 based regimens was 945, 2,132 and 1,636 respectively (Fig.…”

Section: Resultsmentioning

confidence: 99%

Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis

Veer

Ngai

Valkenhoef

et al. 2017

Sci Rep

View full text Add to dashboard Cite

As evidence is inconsistent and based on either isolated Asian or Western studies, we conducted a network meta-analysis (NMA) to examine efficacy and safety of 5-FU (5-fluorouracil), capecitabine and S-1-based first-line treatment of advanced esophagogastric cancer in Asian and Western patients. Medline, EMBASE, CENTRAL and conferences ASCO and ESMO were searched up to January 2016 for randomized-controlled-trials comparing 5-FU, capecitabine or S-1-based regimens with equal chemotherapy backbones. Direct and indirect data for overall survival (OS) and progression-free-survival (PFS) were combined on the Hazard Ratio (HR)-scale using random-effects NMA and calculated as combined HRs and 95%credible intervals (95%CrI). Grade 1-2 and grade 3-4 adverse events were compared with pair-wise meta-analysis. Fifteen studies were identified including capecitabine (n = 945), 5-FU (n = 2,132) or S-1 (n = 1,636). No differences were found in respectively OS and PFS for capecitabine-based versus 5-FU-based regimens (HR = 0.89, 95%CrI = 0.76–1.04 and HR = 0.98, 95%CrI = 0.75–1.32), S-1-based versus 5-FU-based regimens (HR = 0.92, 95%CrI = 0.82–1.04 and HR = 0.88, 95%CrI = 0.70–1.11) and S-1-based versus capecitabine-based regimens (HR = 1.03, 95%CrI = 0.87–1.22 and HR = 0.89, 95%CrI = 0.65–1.20). Effects were similar in Asian and Western subgroups. Toxicity profiles were different but a lower frequency of relevant adverse events was observed with S-1 In conclusion, as efficacy was similar, choosing fluoropyrimidines should be based on their individual toxicity profiles.

show abstract

“…After several days of careful planning, we proposed weekly 5-FU/l-LV and modified to 80% dose of 5-FU(5-FU 500 mg/m 2 , l-LV 250 mg/m 2 on days 1, 8, 15, 22, 29 and 36; 8 weeks/cycle), which has shown non-inferiority to oral fluoropyrimidines against metastatic gastric cancer, as the recommended treatment. This regimen would be useful with a small fluid volume compared to other 5-FU regimens (8).…”

Section: Case Reportmentioning

confidence: 99%

Early administration of systemic chemotherapy should be�considered for scirrhous gastric cancer: A case report

et al. 2018

View full text Add to dashboard Cite

Scirrhous gastric cancer tends to disseminate to the peritoneum and retroperitoneum, where it induces fibrosis. Retroperitoneal fibrosis (RPF) frequently causes acute renal failure due to ureteral obstruction and it tends to make many of physicians hesitate to initiate systemic chemotherapy. The present study reported the case of a 68-year-old man who was diagnosed with scirrhous gastric cancer with peritoneal and retroperitoneal dissemination, causing acute renal failure due to RPF. Before initiating systemic chemotherapy, the patient became anuric and introduced hemodialysis (HD). Although the patient's performance status was poor, there were no contraindications, such as active infection or severe complications, for systemic chemotherapy. Weekly 5-FU/l LV (5-FU 600 mg/m 2 , l-LV 250 mg/m 2 on days 1, 8, 15, 22, 29 and 36; 8 weeks/cycle) was selected as the feasible treatment for the patient. After chemotherapy the patient opted to withdraw from HD and suffered from no severe toxicity. This indicates, retrospectively, that earlier systemic chemotherapy administration prior to HD introduction may result in improvement of renal function and avoidance of HD.

show abstract

6509 5-FU/l-LV (RPMI) versus S-1 as first-line therapy in patients with advanced gastric cancer: a randomized phase III non-inferiority trial. (ISO-5FU10 Study Group trial)

Cited by 17 publications

References 0 publications

Japanese gastric cancer treatment guidelines 2014 (ver. 4)

Japanese gastric cancer treatment guidelines 2014 (ver. 4)

Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis

Early administration of systemic chemotherapy should be�considered for scirrhous gastric cancer: A case report

Contact Info

Product

Resources

About